The mitochondrial proteins TRAP1 and HTRA2 have previously been shown to be phosphorylated in the presence of the Parkinson's disease kinase PINK1 but the downstream signalling is unknown. HTRA2 and PINK1 loss of function causes parkinsonism in humans and animals. Here, we identified TRAP1 as an interactor of HTRA2 using an unbiased mass spectrometry approach. In our human cell models, TRAP1 overexpression is protective, rescuing HTRA2 and PINK1-associated mitochondrial dysfunction and suggesting that TRAP1 acts downstream of HTRA2 and PINK1. HTRA2 regulates TRAP1 protein levels, but TRAP1 is not a direct target of HTRA2 protease activity. Following genetic screening of Parkinson's disease patients and healthy controls, we also report the first TRAP1 mutation leading to complete loss of functional protein in a patient with late onset Parkinson's disease. Analysis of fibroblasts derived from the patient reveal that oxygen consumption, ATP output and reactive oxygen species are increased compared to healthy individuals. This is coupled with an increased pool of free NADH, increased mitochondrial biogenesis, triggering of the mitochondrial unfolded protein response, loss of mitochondrial membrane potential and sensitivity to mitochondrial removal and apoptosis. These data highlight the role of TRAP1 in the regulation of energy metabolism and mitochondrial quality control. Interestingly, the diabetes drug metformin reverses mutation-associated alterations on energy metabolism, mitochondrial biogenesis and restores mitochondrial membrane potential. In summary, our data show that TRAP1 acts downstream of PINK1 and HTRA2 for mitochondrial fine tuning, whereas TRAP1 loss of function leads to reduced control of energy metabolism, ultimately impacting mitochondrial membrane potential. These findings offer new insight into mitochondrial pathologies in Parkinson's disease and provide new prospects for targeted therapies.
Introduction
Parkinson's disease is an aetiologically heterogeneous syndrome caused by a combination of genetic and environmental risk factors. At least 85% of cases are sporadic, and at present, there are only symptomatic treatments available, but the advancement of genetic testing and identification of patient endophenotypes has given hope for the emerging field of individualized medicine. Mitochondrial dysfunction, ensuing cellular energy failure and oxidative stress may be one important disease pathway in a subgroup of Parkinson's disease patients (Kruger et al., 2017) . The aim is that these patients can be therapeutically targeted or serve as an entry point for precision medicine.
TRAP1 (tumour necrosis factor type 1 receptor associated protein, also known as HSP 75) is a chaperone that resides in the mitochondrial matrix (Altieri et al., 2012) . It has a regulatory role in stress sensing in mitochondria allowing cellular adaption to the environment. TRAP1 is recognized as a potential effector protein in Parkinson's disease signalling, since it was found to be phosphorylated by the Parkinson's disease kinase PINK1 (Pridgeon et al., 2007) . Loss-of-function mutations in PINK1 and PARK2 (encoding parkin) cause familial Parkinson's disease (Kitada et al., 1998; Valente et al., 2004) and impair the elimination of damaged mitochondria (Geisler et al., 2010; Narendra et al., 2010) . However, beyond mitophagy, there is relatively little known about the mitochondrial quality control pathways in Parkinson's disease.
Chaperones and proteases maintain mitochondrial proteostasis. Tight control of protein quality and turnover inside mitochondria is essential for the function of electron transport complexes, which provide energy through oxidative phosphorylation. PINK1 has previously been shown to be required for the phosphorylation of the mitochondrial protease and Parkinson's disease-associated protein HTRA2 (Plun-Favreau et al., 2007) . Here we highlight a signalling pathway involving PINK1, HTRA2 and TRAP1, where TRAP1 is the effector modulating mitochondrial chaperone activities and metabolic homeostasis.
The hypothesis that TRAP1 is an important downstream effector in mitochondrial signalling is underscored by reports that TRAP1 rescues mitochondrial dysfunction in neuronal models where PINK1 is silenced (Costa et al., 2013; Zhang et al., 2013) . TRAP1 also protects cells from oxidative toxicity caused by respiratory complex I inhibition via an a-synuclein variant known to induce a genetic form of Parkinson's disease (Butler et al., 2012) . TRAP1 protects mitochondria via its chaperone function (Altieri et al., 2012; Rasola et al., 2014) and by reducing reactive oxygen species (Masuda et al., 2004; Hua et al., 2007; Im et al., 2007) .
TRAP1 also acts as a metabolic switch controlling the tumour cell's preference for aerobic glycolysis (Yoshida et al., 2013) . ERK1/2 orchestrates the phosphorylation of TRAP1 controlling the metabolic switch (Masgras et al., 2017) , which is reportedly via TRAP1 inhibition of succinate dehydrogenase (Sciacovelli et al., 2013; Masgras et al., 2017) , although this remains controversial (Rasola et al., 2014) . TRAP1 deficiency promotes mitochondrial respiration, accumulation of tricarboxylic acid cycle intermediates, ATP and reactive oxygen species (Yoshida et al., 2013) . TRAP1 deletion in mice does not affect viability and delays the appearance of tumours in a breast cancer model (Vartholomaiou et al., 2017) .
Therefore, the identification of TRAP1 as a novel HTRA2 interactor prompted us to further explore the PINK1-HTRA2-TRAP1 pathway related to neurodegeneration in Parkinson's disease. Here we show that TRAP1 takes an important role as downstream effector in this pathway and therefore provides an interface between Parkinson's disease and energy metabolism.
Materials and methods

Cell culture
Fibroblast culture from skin biopsies has been previously described by our laboratory (Burbulla and Kruger, 2012) . All biopsies and DNA samples were obtained with patient's consent and approval of the local ethics committee and according to the Declaration of Helsinki. HeLa, SH-SY5Y, HEK293 cell culture has been described previously (Burbulla et al., 2014) . TRAP1 knockout mouse adult fibroblasts and HTRA2 knockout mouse embryonic fibroblasts have been described by Kieper et al. (2010) and Yoshida et al., (2013) , respectively. Human induced pluripotent stem cells from a PINK1 knockout line generated in our laboratory and its isogenic control were used to generate small molecule neuronal precursor cells (smNPCs) according to Reinhardt et al. (2013) 
DNA constructs and RNAs
Human TRAP1 cDNA was cloned into the pIRES vector (Clontech, Takara). GST-coupled wild-type HTRA2, A141S HTRA2, and G399S HTRA2 have been previously described (Martins, 2002) . Cloning of wild-type HTRA2 and S306A HTRA2 cDNA into the pcDNA3.1 vector was previously described (Strauss et al., 2005) . Short interfering (si)RNAs targeting HTRA2 were purchased from Sigma Aldrich (Fitzgerald et al., 2012) and targeting TRAP1 and non-targeting controls from Dharmacon (siGENOME SMARTpool #D001206-13-05 POOL#1, non-targeting siGENOME SMARTpool).
Mass spectrometry
We used recombinant, mature GST-HTRA2 (wild-type HTRA2, HTRA2-A141S, and HTRA2-G399S) as baits and lysates from SH-SY5Y cells. The supernatant contained the fusion proteins that were then bound to glutathione agarose (Molecular Probes, Thermo Scientific) and eluted with imidazole. Analyses were performed on 1D gel pieces of the eluates. The measurements of the peptides derived from tryptic ingel digest were performed using a nano-HPLC-ESI-MS/MS system [Ultimate (LC Packings/Dionex, Germany)/QStar Pulsar i (Applied Biosystems/Sciex)], described by Sauer et al. (2006) . Mass spectrometry data were processed against the National Center for Biotechnology Information (NCBI) protein sequence database with the search engine MASCOT (Matrix Science, UK) (Perkins et al., 1999) .
Co-immunoprecipitation
HeLa and HEK293 cell lysates were prepared using a lysis buffer [1 % (v/v) Triton TM X-100, 1Â protease inhibitor cocktail (Roche Complete, Roche), 1Â phosphatase inhibitor (Roche PhosStop, Roche)] and the nuclear material removed following homogenization. Where wild-type HTRA2 was overexpressed, HTRA2 was transiently transfected (48 h) using Effectine transfection reagent (Qiagen, according to the manufacturer's instructions). Mitochondrial enrichment was previously described (Fitzgerald et al., 2012) . Brain tissue from TRAP1 knockout mice previously described (Vartholomaiou et al., 2017) was prepared by separating the cortices from the basal ganglia (mid-brain) and cerebellum/brainstem (hindbrain) on ice. Brain tissue lysates were prepared according to Casadei et al. (2016) . Immunoprecipitation was carried out using HTRA2 (R and D Biosciences) or TRAP1 (BD biosciences) antibodies or bovine IgG coupled to protein A Sepharose beads (Sigma Aldrich P9424), according to Fitzgerald et al. (2012) .
SDS-PAGE and western blotting
Cell lysates were prepared as described for co-immunoprecipitation and proteins electrophoresed on acrylamide gels and transferred to membranes, as previously described (Fitzgerald et al., 2012) . Brain tissue lysates from non-transgenic and HTRA2 overexpressing mice previously characterized and described (Casadei et al., 2016) were prepared from whole brain and the total extracts (nuclear material removed) were prepared according to Casadei and colleagues (2016) . Total protein stain (copper pthalocyanine-3, 4', 4' 4'-tetra-sulphonic acid tetra sodium salt in 12 mM HCl) and destain (12 mM NaCl). Antibodies against TRAP1 (BD Biosciences), b-actin (Sigma Aldrich), GAPDH (Invitrogen, Thermo Scientific) Tom20 (Santa Cruz Biotechnology), Hsp60 (Bio-Rad), atubulin (Sigma Aldrich), rodent OXPHOS (#MS604 Mitosciences, AbCam), Hsp70 (Santa Cruz Biotechnology), Hsp90 (BD Biosciences), Human Total OXPHOS (all nuclear encoded subunits from Mitosciences, Abcam), ERK1/2 and P-ERK1/2 (Cell Signaling Technolgy) and mitobiogenesis antibody (containing SDH, GAPDH and COX, Abcam) were used. Secondary antibodies were purchased from GE Healthcare. Densitometry from western blot was carried out using the ImageJ 1.41o software (Wayne Rasband; National Institutes of Health, USA).
Live cell imaging
Mitochondrial morphology, mass and colocalization studies were visualized using 100 nM MitoTracker Õ Green FM (Thermo Scientific), lysosomes by 100 nM Lyostracker Õ Red DND-99 (Thermo Scientific) as previously described (Burbulla et al., 2014) . Analyses were performed as previously described (Burbulla et al., 2014) . The series of images were saved uncompressed and analysed with AxioVision software (Zeiss) and ImageJ 1.41o software.
Fluorescence-activated cell sorting
Cells were trypsinized and centrifuged at 300g for 5 min and the cells incubated in dye, buffer only or dye plus a control. For early apoptosis, Annexin V-Pacific Blue TM in Annexin V binding buffer (both from BioLegend) or Annexin V-Pacific Blue TM plus staurosporine was used. For mitochondrial membrane potential, 200 nM tetramethylrhodamine, ethyl ester, perchlorate (TMRE, from Thermo Scientific) in Hanks buffer or TMRE plus carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (CCCP) 10 mM was used. For mitochondrial reactive oxygen species, 2 mM MitoSox TM (Thermo Scientific) in Hanks buffer or MitoSox TM plus 10 mM rotenone was used. Cells were sorted using a MACSQuant Õ automated flow cytometer (Mitenyi Biotechnology) according to their mean average fluorescence signal. All mean average fluorescence values were divided by the background fluorescence in the same channel in the same unstained cells to account for autofluorescence.
Live cell kinetic measurement of mitochondrial membrane potential Cells were seeded in Ibidi Õ dishes and the media exchanged for Hank's balanced salt solution (HBSS) containing 200 nM TMRE stain (Thermo Scientific) for 15 min at 37 C with CO 2 . The TMRE was removed and replaced with 360 ml Hanks buffer. The cells were imaged using a Zeiss inverted confocal microscope at excitation HeNe1, 543 nm and emission LP 560 nm and brightfield for 20 Â 4 s cycles. Followed by the addition of 360 ml (0.25 mg/ml oligomycin), measured for 20 Â 4 s cycles, 180 ml (10 mM rotenone), measured for 20 Â 4 s cycles and 100 ml (10 mM FCCP) and measured for 20-40 Â 4 s cycles. Using ImageJ, each transfected cell (detected using ZsGreen-TRAP1) in each frame was analysed for TMRE fluorescence intensity, mean fluorescence and total area. The corrected total cell fluorescence (CTCF) over time was calculated using the formula: CTCF = fluorescence intensity À (cell area Â mean background fluorescence).
Genetic screening by high resolution melting analysis
Both polymerase chain reaction (PCR) and high resolution melting analysis were performed in the presence of a saturating DNA binding dye. Mutations were detectable because heterozygote DNA forms heteroduplices that begin to separate in single strands at a lower temperature and with a different curve shape than homozygote DNA, as described previously (Wust et al., 2016) .
Whole exome sequencing and consanguinity analysis Whole exome data were generated from 200 Parkinson's disease patients from Vienna (n = 100) and Tü bingen (n = 100). Genomic DNA (3 mg) was fragmented into $250 bp fragments, end-repaired, adaptor-ligated and sample index barcodes were included. Pooled libraries were enriched with SureSelect Human All Exon 50 Mb kit (AgilentTechnologies) to capture 50 Mb of exonic and flanking intronic regions. Sequencing of post-enrichment libraries was carried out on the Illumina HiSeq 2000 sequencing instrument (Illumina) as 2 Â 100 bp paired-end runs. On average, this yielded $10 Gb of mapped sequences and a 4100Â average coverage for 90% of the targeted sequence per individual. Raw image files were processed by the Illumina pipeline. Reads were aligned to the human reference genome hg19 with the Burrows-Wheeler Aligner. SAM tools were used to identify single nucleotide variants and small insertions and deletions. Patients were screened for consanguinity using an implemented algorithm of an analysing tool of the Helmholtz Zentrum, Mü nchen. Patients with homozygous regions encompassing a total of more than 20 Mb were considered as likely consanguineous. Particularly, stretches of 42 Mb were surveyed for rare homozygous variants (missense, nonsense, frameshift and splice-site). Variants were further filtered for a minor allele frequency smaller than 1% in the in-house dataset of $10 000 control exomes from patients with other unrelated diseases and exomes and in public available databases (ExAC database and 1000 Genomes).
Computational analysis of TRAP1 genetic variants
Computational analysis of TRAP1 variants can be found in the Supplementary material.
Quantitative RT-PCR
Quantitative PCR reactions were performed using FastStart SYBR Õ green Master mix (Roche) to amplify 1 ml of the 1:10 diluted cDNA using 5 mm of each primer h_TRAP1 5' UTR Forward:
TTCCCATCGTGTACGGTCCCGC, h_TRAP1 Exon2 Reverse: GGCCCAACTGGGCTGTGGTCC, h_TRAP1 Spanning Exon2-3 Reverse: TGTTTGGAAGTGGAACCCT GC. Housekeeping gene GAPDH primers: Forward: CCA TCACCATCTTCCAGGAGCGA, Reverse: GGATGACCTT GCCCACAGCCTTG. Standard curves of each amplified gene were created to calculate the PCR efficiency and relative expression using the efficiency corrected delta-delta Ct method. RNA was prepared from human fibroblasts using Qiashredder Õ and RNAEasy Õ preparation kits (Qiagen). RNA (1 mg) was reverse transcribed to cDNA using QuantiTECT Õ (Qiagen).
Oxygen consumption and extracellular acidification rate
Oxygen consumption rates (OCR) were measured in whole cells using a Seahorse TM XF96 Extracellular Flux Analyzer (Agilent) according to Rogers et al. (2011) . The concentrations of mitochondrial toxins used were optimized by titration in human fibroblasts according to the manufacturer's recommendations. The final concentration of all toxins used was 1 mM and the volume of the toxin injected in each port was sequentially increased by several microlitres to maintain the correct final concentration. Human fibroblasts were plated in Seahorse TM XF96 well plates 24 h prior to measuring at a density of $15 000 cells per well. The OCR for each well was corrected for cell number. Stained nuclei were counted using high content image capture and analysis using the BD Pathway 855 (BD Biosciences). Extracellular acidification rates (ECAR) from the same experiments provide an indication of glycolytic activity and were normalized to OCR/cell to account for the cell numbers in each well in each experiment.
Complex I activity
Following isolation of crude mitochondria from approximately five million cells, described previously by Burte et al. (2011) , complex I activity was measured according to Hargreaves and colleagues (2007) . The activity of complex I was normalized to citrate synthase activity, also according to Hargreaves et al. (2007) and data expressed as a ratio of complex I/citrate synthase.
ATP
The concentration of ATP per microgram of total protein was measured using the ATPLite TM Kit from Perkin Elmer. ATP standards are used to determine the concentration of ATP in a cell lysate replicated a minimum of three times in each experiment. Concentration (mM) of ATP is expressed per microgram of total protein in each well as measured by protein assay (BioRad).
Fluorescence lifetime imaging microscopy
A detailed description of the fluorescence lifetime imaging microscopy (FLIM) method can be found in the Supplementary material and is described in Lakner et al. (2017) .
Measurement of NAD
+ /NADH levels NAD + and total NAD + and NADH levels were measured using a fluorometric assay kit (Abcam). The levels of NAD + and NADH were quantified using standards and normalized to total protein in each sample according to protein assay (BioRad).
Statistics
Analyses of statistical significance were performed using GraphPad Prism 6.0 and the relevant statistical test. The statistical test used and the P-values are shown in the figure legends. All cell culture experiments [including all imaging and fluorescence-activated cell sorting (FACS) experiments] were performed a minimum of three times, using a different cell passage and on different days. In the genetic studies, the initial screening by high temperature melt analysis was performed on 280 German Parkinson's disease patients and a group of 192 healthy individuals. The exome sequencing was performed on the DNA from 200 Parkinson's disease patients collected in Tü bingen, Germany and Vienna, Austria.
Results
TRAP1 interacts with HTRA2
We have previously reported loss-of-function mutations in HTRA2 in Parkinson's disease patients and therefore performed unbiased mass spectrometry on GST-HTRA2 baited SH-SY5Y lysates to identify novel interaction proteins (Fig. 1A ). We identified TRAP1 as an interactor of HTRA2 with the relevant controls.
To confirm the physical interaction, HTRA2 immunoprecipitations were performed in HeLa cells overexpressing HTRA2 or not. Immunoblotting revealed the presence of TRAP1 in the HTRA2 immunoprecipitation (endogenous and overexpressed HTRA2) but not in the IgG control (Fig. 1B) , enriched in the mitochondrial fraction. Knockdown of TRAP1 using siRNA reduced the amount of TRAP1 interacting with HTRA2, confirming the specificity of the immunoprecipitation (Fig. 1C) . The interaction between HTRA2 and TRAP1 occurs in mouse brain (cortex, midbrain and hindbrain) as demonstrated by the immunoprecipitation of TRAP1 with HTRA2 in extracts from wild-type mice and not TRAP1 knockout mice (Fig. 1D) .
To investigate the relevance of the HTRA2-TRAP1 interaction we monitored the amount of TRAP1 immunoprecipitated with HTRA2 under several stress conditions. We found that acute treatment with the mitochondrial toxins rotenone and antimycin A abolished the interaction in human HEK293 cells and this was due to reduced TRAP1 and not a global reduction of total protein (Fig. 1E) . We then assessed the influence of several other stressors, this time the concentrations of the toxins were titrated for HeLa cells and for the cells to survive a chronic treatment over a 24 h period. We found that dopamine treatment had no effect on the interaction of HTRA2 and TRAP1, whereas, the TRAP1 inhibitor 17-AAG, hydrogen peroxide, the ionophore valinomycin and mitochondrial respiratory inhibitors oligomycin, antimycin A, and rotenone all largely reduced or abolished the interaction (Fig. 1F ). These data from two different human cell lines suggest that the interaction of HTRA2 and TRAP1 serves the mitochondria under normal physiological conditions, under starvation and dopamine toxicity, but not respiratory inhibition.
TRAP1 rescues HTRA2 and PINK1 loss-of-function phenotypes but is not a proteolytic substrate of HTRA2
We hypothesized that HTRA2 interacted with TRAP1 to degrade it since HTRA2 is a key mitochondrial protease and the levels of TRAP1 appear to be a key factor in mitochondrial control (Kang et al., 2007; Zhang et al., 2015; Amoroso et al., 2016; Lv et al., 2016) . Using PhosTag TM SDS-PAGE, we found a significant increase in the levels of phosphorylated and non-phosphorylated TRAP1 when we immunoprecipitated endogenous TRAP1 in the absence of HTRA2 ( Fig. 2A) . We also found that stimulation of PINK1 kinase with the ionophore valinomycin (at concentrations known to induce accumulation of PINK1) (Rakovic et al., 2013) , increased the amount of phosphorylated TRAP1 in wild-type HTRA2 mouse adult fibroblasts ( Fig. 2A) . Phosphorylated TRAP1 levels were increased to the same extent in HTRA2 knockout mouse adult fibroblasts, whether treated with valinomycin or not ( Fig. 2A) . However, there was no significant effect of PINK1 knockout on TRAP1 phosphorylation status in neuronal progenitor cells ( Fig. 2A) .
Overexpression of wild-type HTRA2 in human cells from four independent experiments (Fig. 2B ) or in mice (Fig. 2C ) results in reduced TRAP1 protein levels. However, overexpression of a protease dead form of HTRA2 (S306A), which is catalytically inactive but still targeted to the mitochondria in human cells has the same effect on TRAP1 levels as the wild-type, indicating that the protease activity of HTRA2 is not important for the interaction between TRAP1 and HTRA2 (Fig. 2D) .
The HTRA2-TRAP1 interaction is not a protease-substrate interaction, yet TRAP1 is likely downstream of HTRA2 since the overexpression of TRAP1 rescues the HTRA2 knockdown-induced loss of mitochondrial membrane potential (Fig. 2E) , reduced basal oxygen consumption (Fig. 2F) , increased mitochondrial reactive oxygen species (Fig. 2G ) and sensitivity towards serum starvation-induced apoptosis (Fig. 2H ). TRAP1 overexpression also rescues the reduced mitochondrial membrane potential observed in PINK1-deficient neuroprogenitor cells measured over a time course inclusive of mitochondrial toxin controls (Fig. 2I ).
TRAP1 loss-of-function in Parkinson's disease
Mutations in PINK1 cause early onset Parkinson's disease (Valente et al., 2004) Supplementary Fig. 1A ). The residues for variants S221P and R469C are largely buried (5% and 13% solvent accessibility), whereas variant H311Q affects a residue that is partially accessible (25%) and could alter protein-protein interactions via residue size and charge alterations. In a multiple sequence alignment, high sequence conservation was observed for residues H311 and R469, but not for S211 ( Supplementary Fig. 1B ). Correspondingly, a destabilizing effect was predicted by the majority of algorithms for H331Q and R469C, while the S221P variant was estimated to be neutral. Notably, R469C was also predicted to decrease the chaperone binding function of TRAP1 (LIMBO software). We used high resolution melting to screen for sequence variations in the TRAP1 gene in the genomic DNA from German Parkinson's disease patients and a group of healthy individuals. We detected several genetic variants, further identified as single nucleotide polymorphisms (listed in Supplementary Fig. 1C ). Burden analysis of TRAP1 was performed using the PPMI dataset (summarized in Supplementary Fig. 1D ). Truncating variants predicted to cause loss-of-function of TRAP1 are very rare and were only observed in Parkinson's disease patients and not in controls. Interestingly, rare missense TRAP1 mutations were found to have significantly different burden (P-values 5 0.05) between patients and controls ( Supplementary Fig. 1D ). In parallel, we analysed 200 exomes of Parkinson's disease patients from Austria and Germany for consanguinity. In addition to TRAP1 variants (listed in Supplementary Fig. 1C ), we found a moderate, but significant consanguinity of $20 Mb in a German Parkinson's disease patient. One homozygous stretch encompasses 5 Mb at Chr.16, including the TRAP1 gene. Here we found a homozygous c.C1584T (R47X) mutation (Fig. 3A) . This mutation is not present in 10 000 control exomes of the Helmholtz database; however, it occurs 12 times heterozygously in the ExAC database (60 000 controls). The R47X TRAP1 Parkinson's disease patient has no rare variant in any of the other established Parkinson's disease genes (see Supplementary material for the full list of genes).
The homozygous p.Arg47Ter single nucleotide exchange (R47X) in exon 2 of TRAP1 leads to a premature stop codon and truncation at the transit sequence of TRAP1 in a late-onset Parkinson's disease patient (Fig. 3A) . A TRAP1 antibody that binds at a region of TRAP1 encompassing amino acids 253-464 (shown in Fig. 3B ) was, as expected, unable to detect TRAP1 protein in fibroblasts biopsied from the R47X patient (Fig. 3C ). Using PCR primers upstream and downstream of the mutation to amplify patient cDNA, we found that TRAP1 RNA is present, suggesting no nonsense-mediated RNA decay (Fig. 3D) . The R47X TRAP1 patient was diagnosed with Parkinson's disease at age 70 years. There is no family history of Parkinson's disease but the mother of the index patient had dementia. The R47X patient has also been diagnosed with dilated cardiomyopathy, chronic pancreatitis, polyneuropathy and chronic kidney insufficiency (Table 1) .
TRAP1 R47X Parkinson's disease patient mitochondria meet ATP demand but have reduced membrane potential
To understand the relevance of the R47X TRAP1 mutation, we assessed several readouts of mitochondrial form and function in patient-derived fibroblasts. There were no obvious differences in mitochondrial morphology between controls and the index patient under basal or serum starvation conditions (binary z-stack images shown in Fig. 4A ). Confocal images were taken every 4 s following incubation with TMRE, followed by washing (basal), oligomycin (oligo), rotenone (rot) and FCCP (fccp). All statistical tests were the Student's t-test assuming different standard deviation, except 2H, where two-way ANNOVA was used to compare groups and condition. Error bars show standard deviation and *P 5 0.05; **P 5 0.01. TMRE = tetramethylrhodamine, ethyl ester, perchlorate.
Computational analysis of z-stack images revealed no difference in average mitochondrial size (Fig. 4B ) or mitochondrial branching (Fig. 4C) . However, after serum starvation there was a significant fragmentation of mitochondria in the R47X fibroblasts compared to controls (Fig. 4D) . We measured the co-localization of mitochondria and lysosomes in patient and control fibroblasts and the results show similar co-localization of mitochondria with lysosomes under normal physiological conditions. Following mild induction of autophagy by serum withdrawal, we found that mitochondria to lysosome translocation was more pronounced in TRAP1 R47X cells (Fig. 4E) , suggesting increased mitochondrial turnover.
Respiratory analysis of patient cells and controls, recorded oxygen consumption during a mitochondrial stress test, where minimal, maximal and inhibited respiration is induced by oligomycin, the uncoupler FCCP and antimycin A, respectively (Fig. 4F) . Basal respiration was significantly increased in R47X fibroblasts (Fig. 4F) . The extracellular acidification rate (an indicator of glycolysis) normalized to the rate of oxygen consumption per cell in R47X fibroblasts was generally higher than that of healthy controls (Fig. 4G) . However, the calculated glycolytic shift after the addition of oligomycin is similar between patient and controls ( Fig. 4G) . Complex I enriched in mitochondrial extracts of R47X cells was significantly more active in oxidizing NADH given as a substrate along with decylubiquinone in vitro than healthy individuals (Fig. 4H) . Furthermore, significantly more ATP was produced in R47X fibroblasts compared to controls (Fig. 4I) , indicating that the complexes of the respiratory chain are not damaged and suggesting that mitochondria in R47X patient cells have increased respiratory activity.
TRAP1 deficiency is reported to promote increases in mitochondrial respiration, ATP levels and reactive oxygen species in mice (Yoshida et al., 2013) . Therefore, we identified the index patient in a previous study measuring mitochondrial reactive oxygen species in sporadic Parkinson's disease patient fibroblasts. The index patient has above average levels of mitochondrial reactive oxygen species, but are only mildly elevated in comparison to several other sporadic Parkinson's disease patients, genetic Parkinson's disease (PINK1, parkin and DJ-1 patients) and Leigh syndrome patient fibroblast lines (Fig. 4J) . Finally, mitochondrial membrane potential was significantly reduced in TRAP1 R47X fibroblasts compared to controls (Fig. 4K) .
Metformin rescues the R47X phenotype via a mechanism involving mitochondrial biogenesis
In ovarian cancer, TRAP1 silencing causes resistance to chemotherapy drugs because oxidative phosphorylation is increased. Interestingly, the resistance to chemotherapy could be reversed by mild inhibition of mitochondrial respiration by the diabetes drug metformin or oligomycin . Therefore, we treated TRAP1 R47X patient fibroblasts with 10 mM metformin, sublethal concentrations of oligomycin and the antioxidant N-acetyl cysteine (NAC) to see whether we could rescue the patient phenotype. Metformin and oligomycin treatment restored the mitochondrial membrane potential observed in the patient, whereas the antioxidant NAC could not (Fig. 5A) .
We subjected human cancer cells to a range of toxins and stressors and measured their effect on mitochondrial membrane potential. Dopamine, hydrogen peroxide and the ionophore valinomycin greatly reduced mitochondrial membrane potential and this could not be rescued by metformin. Dopamine toxicity was protected by addition of the antioxidant NAC and metformin treatment alone does not reduce mitochondrial membrane potential (Fig. 5B) . Finally, reduced mitochondrial membrane potential induced by the Hsp90 family/TRAP1 inhibitor 17-AAG could be reversed by metformin (Fig. 5B) , suggesting there is a specific effect of metformin in paradigms related to TRAP1.
To investigate further the mechanism by which metformin is protective in our model, we measured the fluorescence lifetime of NADH in living cells from the TRAP1 R47X patient and healthy individuals with and without treatment with metformin. Bound NADH indicates usage in mitochondrial respiration, whereas free NADH is associated with glycolysis (Bird et al., 2005; Blacker et al., 2014) . We found significantly reduced bound NADH and increased free NADH following metformin treatment in all cell types (Fig. 5C ). This finding supports the observation that metformin suppresses gluconeogenesis (Kim et al., 2008) , inhibits complex I (Owen et al., 2000) and shifts the balance between coupling and uncoupling reactions via the TCA cycle (Andrzejewski et al., 2014) . We found a similar bound/unbound NADH ratio in the untreated R47X patient fibroblasts as in the metformin treated controls and the addition of metformin in the patient did not reverse the bound/unbound NADH ratio (Fig. 5C ). These data, although highly significant, represent overall a very small shift in the total levels of bound versus unbound NADH levels (Fig. 5C ). The data suggest that the protective mechanism of metformin in the R47X patient is not via the metabolic switch between oxidative phosphorylation (OXPHOS) and glycolysis. These data could mean that either glycolysis is favoured in the R47X patient or mitochondrial turnover and/or the NAD + /NADH pool are altered. NAD + and combined NAD + and NADH levels are significantly increased in TRAP1 R47X patient cells compared to controls (Fig. 5D ). Metformin treatment in healthy individuals and in TRAP1 R47X patient cells lowers both NAD + and total NAD + and NADH levels in one control and the patient, but not significantly (Fig. 5D) .
We observe a significantly reduced ratio of succinate dehydrogenase (SDH) to cytochrome c oxidase (COX mtDNA-encoded subunit) in both R47X patient fibroblasts and TRAP1 knockout mouse adult fibroblasts compared to controls (Fig. 5E) , which indicates an imbalance between nuclear and mitochondrially encoded mitochondrial proteins (termed mitonuclear imbalance), likely induced by the increased NAD + and NADH pool and in agreement with the effect of NAD + boosters on the age-associated metabolic decline and promotion of longevity in worms .
Metformin is able to reverse the mitonuclear imbalance in the TRAP1 R47X patient fibroblasts (Fig. 5E ), indicating that the mitonuclear imbalance is the converging step in the survival pathway that can be targeted pharmacologically. Mitonuclear protein imbalance controls longevity in mammals via induction of the mitochondrial unfolded protein response (mtUPR) Mouchiroud et al., 2013) . Therefore, we monitored the levels of Hsp60, Hsp70 and mitochondrial Hsp90, three markers of the mtUPR. We found that on average both Hsp60 and mtHsp70 levels were higher in R47X TRAP1 patient fibroblasts compared to two healthy controls in three independent experiments (Fig. 5F ). Hsp90 levels were also elevated but the difference was not significant (Supplementary Fig.  2C ). These data suggest that in TRAP1 loss-of-function models, the mtUPR is upregulated. This is associated with increased turnover of mitochondria and the significant elevation of subunits of mitochondrial respiratory complexes I, II, III and IV, which is also rescued by metformin ( Supplementary Fig. 2B ). Phosphorylated ERK1/2 orchestrates metabolic switching via TRAP1 (Masgras et al., 2017) . Here we found that the levels of phosphorylated ERK1/2 are increased in the index patient fibroblasts and can be reversed by metformin (Supplementary Fig. 2D ).
Discussion
TRAP1 and HTRA2 are targets of the Parkinson's disease kinase PINK1 (Plun-Favreau et al., 2007; Pridgeon et al., 2007) . However, how these three proteins act together in Parkinson's disease signalling still remains to be elucidated. One of the barriers to dissecting a pathway involving HTRA2 and TRAP1 was the lack of mechanistic evidence for the downstream mitochondrial function observed.
Here we have shown that HTRA2 and TRAP1 physically interact and regulate each other. The biochemistry of the interaction is non-canonical and does not involve the protease activity of HTRA2, leaving us to speculate that HTRA2 and TRAP1 perform in a common intra-mitochondrial chaperoning or quality control system. In this study, overexpression of the catalytically inactive HTRA2 S306A reduces TRAP1 protein levels to the same extent as wild- . The Student's t-test was used assuming different standard deviation to compare patient and control group. Two-way ANOVA was used to compare cell types and treatments. Error bars show standard deviation and *P 5 0.05; **P 5 0.01 and ***P 5 0.001.
type HTRA2. As in mnd2 mice carrying the S276C HTRA2 mutation, HTRA2 is catalytically inactive and as the mice phenocopy the mitochondrial dysfunction and neurodegeneration seen in HTRA2 knockout mice (Martins et al., 2004) , S306A is also unlikely to rescue HTRA2 loss of mitochondrial function. However, HTRA2 possesses chaperone activity in its basal state (Li et al., 2002) . Protease dead HTRA2 could still bind TRAP1 via its PDZ domain. The PDZ domain of HTRA2 has a 'YIGV' recognition pattern but also detects long hydrophobic stretches , preferentially C-terminal peptides (Clausen et al., 2002) . Interestingly, analysis of TRAP1 hydrophobicity shows a hydrophobic stretch at the C-terminal (Supplementary Fig.  2A ) and therefore an alternative mode of interaction by association should not be ruled out. Other mitochondrial proteases could also be influencing TRAP1 and loss of HTRA2 could trigger other proteases in order to maintain proteostasis, which displays some redundancy. One concept that links HTRA2 and TRAP1 in the context of neurodegeneration is the mtUPR. The mtUPR is a highly conserved cellular response activated when the accumulation of unfolded or misfolded proteins goes beyond the chaperone capacity of the mitochondria (Pellegrino et al., 2013) . The mtUPR activates transcription of nuclear-encoded mitochondrial chaperone genes to promote protein homeostasis within mitochondria. HTRA2 levels are increased during mtUPR (Spiess et al., 1999) and loss of HTRA2 contributes to transcriptional stress response (Moisoi et al., 2009) . Overexpression of TRAP1 activates mtUPR and extends lifespan in Drosophila (Baqri et al., 2014) and TRAP1 inhibition promotes the mtUPR response in Caenorhabditis elegans (Munch and Harper, 2016) .
TRAP1 gain-of-function rescues PINK1 (Zhang et al., 2013) and PINK1/parkin loss-of-function in Drosophila (Costa et al., 2013 ) and here we can show that TRAP1 rescues HTRA2 and PINK1 loss-of-function in human cells. In addition to its role as a chaperone, TRAP1 is also involved in metabolic switching (Yoshida et al., 2013; Sciacovelli et al., 2013; Rasola et al., 2014; Masgras et al., 2017) and therefore through the identification of a sporadic Parkinson's disease patient homozygous for a premature stop mutation in TRAP1 and data from the patient fibroblasts, we have uncovered a mechanism involving mitochondrial metabolism.
TRAP1 mutations could be important for our understanding of the underlying biological mechanisms that lead to Parkinson's disease and although the role and influence of rare variants in complex diseases is a debated subject, data generated so far indicate that common and rare variants are not mutually exclusive. We used the PPMI repository (with 380 Parkinson's disease cases and 162 controls) to perform a comprehensive burden analysis. Truncating variants predicted to cause loss-of-function of TRAP1 are very rare and were only observed in Parkinson's disease patients and not in controls. For rare missense TRAP1 mutations, we found a significantly different burden (P-values 5 0.05) between patients and controls. We also investigated whether there are healthy individuals who have both alleles of the TRAP1 gene inactivated. Using our in-house Helmholtz database and several available large datasets, we found no such TRAP1 mutation, showing that biallelic loss-of-function mutations are not well tolerated in healthy individuals. Overall, the result of the burden analysis points to an association of TRAP1 rare, missense variants in controls that may be protective for Parkinson's disease. To further validate the findings on low frequency variants in Parkinson's disease, we would need independent, larger sample sets.
In 2014, Luykx et al. (2014) hinted that TRAP1 variants are associated with neurotransmitter metabolism and Parkinson's disease. The authors performed a genomewide association study (GWAS) analysis and found a significant association of the ratio of HVA/5-HIAA, indicating enhanced monoamine turnover in variants of six genes, among them were PINK1 and TRAP1, further supporting the genetic contribution of TRAP1 to Parkinson's disease.
In the case reported here, a homozygous stop mutation in TRAP1 in a Parkinson's disease patient leads to complete loss of the TRAP1 protein. TRAP1 mutations have previously been associated with chronic pain, fatigue and gastrointestinal dysmotility (Boles et al., 2015) , a recognized common dysfunction in Parkinson's disease (Pfeiffer, 2003) . One highly conserved variant in this study (p.Ile253Val) was also identified in both German and Austrian Parkinson's disease patients. Furthermore, recessive mutations in TRAP1 were identified in two families with congenital abnormalities of the kidney and urinary tract (CAKUT) and VACTERL association (congenital abnormalities in multiple organs) (Saisawat et al., 2014) . Interestingly, the late-onset Parkinson's disease patient with a homozygous stop mutation (R47X) in TRAP1 described here was also diagnosed with chronic pancreatitis and, chronic kidney insufficiency but not diabetes. The R47X patient also shows other symptoms related to mitochondriopathies such as cardiomyopathy, polyneuropathy, sleep apnoea and cataracts. Studies in mice have shown that TRAP1 overexpression protects against cardiac hypertrophy (Zhang et al., 2011) and underscores the link between TRAP1 defects and mitochondriopathy.
In line with previous work performed in TRAP1 knockout mice (Yoshida et al., 2013) , TRAP1-deficient patient fibroblasts show increased respiration, complex I activity and ATP output. We also found more unbound NADH, which indicates favouring of glycolysis. However, these changes, although highly significant, are overall very small, which might reflect the low metabolic demand in fibroblasts compared to neurons. Unbound NADH could also come from the NAD + /NADH pool, which is increased in mitochondrial biogenesis. NAD + metabolism engages key effectors of longevity, and interestingly modulating NAD + levels has become a focus for intervention in agerelated diseases (Karpac and Jasper, 2013) . NAD + signals mitochondrial biogenesis via the sirtuin pathway, this impacts mitonuclear protein balance and initiates the mtUPR, promoting longevity .
Altered stoichiometry between nuclear and mtDNA encoded proteins (mitonuclear protein balance) is a conserved longevity mechanism across many species. Mitonuclear protein imbalance is coupled with the activation of the mtUPR, activation of mitochondrial chaperones and longevity . Mitochondrial biogenesis, normal ageing, mitochondrial transcription and translation all influence the balance of nuclear and mtDNA encoded mitochondrial proteins .
The diabetes mellitus type 2 drug metformin was investigated in this study because of its ability to reverse TRAP1-dependent chemotherapy resistance in ovarian cancer . The ability of metformin (and not an antioxidant) to rescue the reduced mitochondrial membrane potential phenotype is of particular interest as metformin has previously been shown to be protective in Parkinson's disease models (Patil et al., 2014; PerezRevuelta et al., 2014) and there are significantly fewer cases of Parkinson's disease in diabetes mellitus type 2 patients taking metformin (Wahlqvist et al., 2012) . We propose that loss of TRAP1 hinders the fine tuning of energy metabolism, proteostasis and the mtUPR response. It is this fine tuning that over time, when not available, pushes the cell in favour of meeting immediate energy needs, rather than energy restriction. Further work to generate induced pluripotent stem cells from the TRAP1 R47X patient fibroblasts and gene correct the mutation would confirm cause of disease. In conclusion, loss-of-function mutations in TRAP1 are rare, yet analyses of the biological pathway involving TRAP1, show that TRAP1 is important for mitochondrial signalling in Parkinson's disease. These data also underscore the role of rare variants in the pathogenesis of Parkinson's disease and suggest that treatments other than antioxidants should also be considered for individualized therapies in aetiologically heterogeneous syndromes such as Parkinsonism.
